title: Alleviation of gallbladder complications by treatment of hepatic arterial embolization with caerulein.
abstract: Transcatheter arterial embolization (TAE) with the concurrent use of caerulein was assessed for the purpose of preventing gallbladder complications often seen after TAE of hepatic carcinoma. Ninety-six cases with primary hepatic carcinoma, who had undergone TAE in the right hepatic arterial region over the past 4 years, were divided into three groups: 22 cases for which embolization was possible on a selective basis by passing the catheter to the peripheral side beyond the bifurcated region of the cystic artery; 40 cases who had undergone TAE in which caerulein was not administered, from the central side of the bifurcated region of the cystic artery; and 34 cases given 20 micrograms caerulein 15-30 min before TAE. A comparison was made using the abdominal pain, pyrexia, rate of leukocytosis and the US findings of the gallbladder as the indices of the gallbladder complications. As a result, it became evident that it was possible to prevent or alleviate gallbladder complications if caerulein were administered before TAE in cases where the embolizing substances were infused in the right hepatic artery from the central side of the bifurcated region of the cystic artery. It was conclusively shown that the gallbladder blood flow decreases if the organ is contracted by caerulein, which in turn causes a decrease in the inflow of the embolizing substances whereby complications are alleviated.
authors.affiliation: 3rd Internal Medicine, Medical Department, Ehime University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Akamatsu
authors.forename: S
authors.initials: S
authors.lastname: Miyauchi
authors.forename: K
authors.initials: K
authors.lastname: Ohshima
authors.forename: S
authors.initials: S
authors.lastname: Okita
authors.forename: Y
authors.initials: Y
authors.lastname: Yasuhara
authors.forename: H
authors.initials: H
authors.lastname: Mogami
authors.forename: Y
authors.initials: Y
authors.lastname: Ohta
authors.forename: K
authors.initials: K
authors.lastname: Hamamoto
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D002108:Ceruletide / Q000627:therapeutic use*; D002765:Cholecystography; D004621:Embolization, Therapeutic / Q000009:adverse effects*; D005260:Female; D005704:Gallbladder / Q000098:blood supply*; D006499:Hepatic Artery; D006801:Humans; D007238:Infarction / Q000517:prevention & control*; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D002108:Ceruletide